Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder
The DOI matches its Crossref record, with a small difference in title or year; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cariprazine is an atypical antipsychotic currently under investigation as adjunctive therapy in patients with major depressive disorder (MDD) who have inadequate response to standard antidepressant therapy. METHOD: A randomized, double-blind, placebo-controlled, flexible-dose study was conducted from December 2011 to December 2013 in adults who met DSM-IV-TR criteria for MDD and had an inadequate antidepressant response. Eligible patients were randomized to 8-week adjunctive treatment with placebo (n = 269), cariprazine 1-2 mg/d (n = 274), or cariprazine 2-4.5 mg/d (n = 276). The primary efficacy parameter was change from baseline to week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) total score; P values were adjusted for multiple comparisons. Safety assessments included adverse events, clinical laboratory tests, vital signs, electrocardiograms (ECGs), and suicidality. RESULTS: Compared with placebo, reduction in MADRS total score at week 8 was significantly greater with adjunctive cariprazine 2-4.5 mg/d (least squares mean difference [LSMD] = -2.2; adjusted P = .0114), but not with cariprazine 1-2 mg/d (LSMD = -0.9; adjusted P = .2404). Significant LSMDs for MADRS total score change were detected at all earlier study visits (weeks 2, 4, 6) in the 2- to 4.5-mg/d group and at weeks 2 and 4 in the 1- to 2-mg/d group (all P values < .05). Treatment-emergent adverse events reported in ≥ 10% of patients in either cariprazine dosage group were akathisia (22.3%), insomnia (13.6%), and nausea (12.8%) (all in 2- to 4.5-mg/d group). Mean changes in metabolic parameters, vital signs, and ECG parameters were generally similar between groups. No suicide-related adverse events were reported. DISCUSSION: These results show that adjunctive cariprazine 2-4.5 mg/d was effective and generally well tolerated in adults with MDD who had inadequate responses to standard antidepressants. Further clinical studies to confirm these results are warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01469377.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, cariprazine currently FDA approved for treatment of schizophrenia and bipolar-type I disorder has been studied as an adjunctive agent for MDD showed a significant reduction in MADRS scores at week 8 compared to placebo (Durgam et al., 2016; Earley et al., 2018).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Durgam et al., 2016
Citations
Cites
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
(2007) · PubMed · Cited by 453
Management of nonresponse and intolerance: switching strategies.
D, M. F. M. (2000) · PubMed · Cited by 103
Second-generation antipsychotics in the treatment of major depressive disorder: current evidence
Han, C., Wang, S.-M., Kato, M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811901 · Cited by 92
Wright, B. M., Eiland, E. H., & Lorenz, R. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1204 · Cited by 84
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Earley, W. R., Burgess, M. V., Khan, B., Rekeda, L., Suppes, T., Tohen, M., & Calabrese, J. R. (2020) · Bipolar Disorders · doi:10.1111/bdi.12852 · Cited by 247
Self-citationStahl, S. M., Laredo, S., & Morrissette, D. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320905752 · Cited by 223
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
Vieta, E., Earley, W. R., Burgess, M. V., Durgam, S., Chen, C., Zhong, Y., Barabássy, Á., & Németh, G. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000246 · Cited by 191
“Cariprazine was safe and efficacious in an 8-week study in adults with depressive episodes associated with bipolar depression (Durgam et al., 2016c) and in a previous 8-week study as an adjunctive treatment to ADT in adults with MDD (Durgam et al., 2016a).”
BackgroundResultSelf-citationPharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
Antidepressants in bipolar depression: An enduring controversy
Gitlin, M. J. (2018) · International Journal of Bipolar Disorders · doi:10.1186/s40345-018-0133-9 · Cited by 116
Correll, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., Kraemer, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 109
Collo, G., Cavalleri, L., Bono, F., Mora, C., Fedele, S., Invernizzi, R. W., Gennarelli, M., Piovani, G., Kunath, T., Millan, M. J., et al. (2018) · Neural Plasticity · doi:10.1155/2018/4196961 · Cited by 112
“An involvement ofD3R inmooddisorders is further supported by recent positive trials in insufficiently responsive patients withmood disorders treated with cariprazine, a D2R/D3R partial agonist with a 10-fold preferential affinity to D3R [59, 60].”
Current drug treatments targeting dopamine D3 receptor
Leggio, G. M., Bucolo, C., Platania, C. B. M., Salomone, S., & Drago, F. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.007 · Cited by 110
Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
Experimental medication treatment approaches for depression
Ionescu, D., & Papakostas, G. I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.33 · Cited by 83
Pharmacological interventions for treatment-resistant depression in adults
Davies, P., Ijaz, S., Williams, C. J., Kessler, D., Lewis, G., & Wiles, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010557.pub2 · Cited by 73
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P.-M. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 74
“One phase II RCT [76] evaluated the efficacy and safety of cariprazine as adjunctive therapy in patients with MDD who”
BackgroundMethodInfluentialKiss, B., Laszlovszky, I., Krámos, B., Visegrády, A., Bobok, A. Á., Lévay, G. I., Lendvai, B., & Román, V. (2021) · Biomolecules · doi:10.3390/biom11010104 · Cited by 83
Self-citationCaraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 73
Cutler, A. J., Durgam, S., Wang, Y., Migliore, R., Lu, K., Laszlovszky, I., & Németh, G. (2017) · CNS Spectrums · doi:10.1017/s1092852917000220 · Cited by 77
Self-citationSachs, G. S., Yeung, P. P., Rekeda, L., Khan, A., Adams, J., & Fava, M. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220504 · Cited by 72
“5 mg/day was more effective than placebo in improving depressive symptoms in adultswithMDD(22).”
BackgroundDurgam, S., Greenberg, W. M., Li, D., Lu, K., Laszlovszky, I., Nemeth, G., Migliore, R., & Volk, S. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4450-3 · Cited by 64
“Of note, cariprazine has demonstrated efficacy in clinical studies as monotherapy for bipolar I depression and as adjunctive therapy for major depressive disorder (Durgam et al. 2016a; Durgam et al. 2016c).”
BackgroundSelf-citationFava, M., Durgam, S., Earley, W., Lu, K., Hayes, R., Laszlovszky, I., & Németh, G. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000235 · Cited by 58
“…but not statistically significant, reduction (improvement) in depressive symptoms from baseline, compared with placebo, of cariprazine 1.0–2.0mg/ day that is reported, is consistent with the results of adjunctive cariprazine 2.0–4.5mg/day from another placebocontrolled trial (Durgam et al., 2016a).”
BackgroundResultSelf-citationDopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Mohr, P., Masopust, J., & Kopeček, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.781946 · Cited by 67
Kiss, B., Némethy, Z., Fazekas, K., Kurkó, D., Gyertyán, I., Sághy, K., Laszlovszky, I., Farkas, B., Kirschner, N., Terjéki, E., et al. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s188760 · Cited by 63
Self-citationDemyttenaere, K., Detraux, J., Racagni, G., & Vansteelandt, K. (2019) · CNS Drugs · doi:10.1007/s40263-019-00625-3 · Cited by 56
Lao, K. S. J., He, Y., Wong, I. C. K., Besag, F., & Chan, E. W. (2016) · CNS Drugs · doi:10.1007/s40263-016-0382-z · Cited by 53
“The treatment intervention in one of the included RCTs was a combination of cariprazine and antidepressant [22], whereas it was cariprazine alone in the other eight RCTs.”
BackgroundInfluentialKehr, J., Yoshitake, T., Ichinose, F., Yoshitake, S., Kiss, B., Gyertyán, I., & Adham, N. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4874-z · Cited by 50
“Moreover, cariprazine has demonstrated efficacy in patients with bipolar depression and as adjunctive treatment in patients with major depressive disorder (Durgam et al. 2016a; Durgam et al. 2016b).”
Roméo, B., Blecha, L., Locatelli, K., Benyamina, A., & Martelli, C. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118760661 · Cited by 52
Citrome, L. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s159704 · Cited by 50
“An active clinical development plan includes studies in bipolar I depression(60) and major depressive disorder.(61) Cariprazine also differs from other oral antipsychotics in terms of the extended half-life of its major active metabolite – DDCAR.”
Earley, W. R., Guo, H., Németh, G., Harsányi, J., & Thase, M. E. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4578 · Cited by 44
Self-citationTreating depression with adjunctive antipsychotics
Mulder, R., Hamilton, A., Irwin, L., Boyce, P. M., Morris, G., Porter, R., & Malhi, G. S. (2018) · Bipolar Disorders · doi:10.1111/bdi.12701 · Cited by 44
Townsend, M., Pareja, K., Buchanan-Hughes, A., Worthington, E., Pritchett, D., Brubaker, M., Houle, C. R., Mose, T. N., & Waters, H. C. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s343211 · Cited by 47
Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence
Chow, C. L., Kadouh, N. K., Bostwick, J. R., & VandenBerg, A. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2404 · Cited by 40
Brexpiprazole for treatment-resistant major depressive disorder
Fornaro, M., Fusco, A., Anastasia, A., Cattaneo, C. I., & Berardis, D. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1654457 · Cited by 39
“However, cariprazine is not approved as an augmentation strategy for MDD showing an inadequate response to an antidepressant, albeit being under scrutiny even for such potential use[34].”
BackgroundGrigolon, R. B., Trevizol, A. P., Gerchman, F., Bambokian, A. D., Magee, T., McIntyre, R. S., Gomes, F. A., Brietzke, E., & Mansur, R. B. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.032 · Cited by 35
Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 37
Review of cariprazine in management of psychiatric illness
Campbell, R. H., Diduch, M., Gardner, K. N., & Thomas, C. J. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.221 · Cited by 37
“Additionally, QTc prolongation, vital sign abnormalities, and significant liver enzymes elevation (although there was 1 report of suspected druginduced hepatitis with a cariprazine 12 mg/d regimen) did not occur more frequently in cariprazine-treated patients compared with placebo-treated patients.(4-13)”
BackgroundResultInfluentialPharmacotherapy for Treatment-Resistant Depression
Vas, C., Jain, A., Trivedi, M., Jha, M. K., & Mathew, S. J. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.012 · Cited by 32
Corponi, F., Serretti, A., Montgomery, S., & Fabbri, C. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000189 · Cited by 35
“Further, one of the relevant studies (Durgam et al., 2016a) was excluded from our primary analysis because it estimated an improvement in the PANSS total score using a different approach compared with PANSS subscales and other scales.”
InfluentialSelf-citationVasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884143 · Cited by 34
Montano, C. B., Jackson, W., Vanacore, D., & Weisler, R. H. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2189868 · Cited by 31
“and the need for early and aggressive monitoring and treatment modifications with measurement-guided care [91,92].”
BackgroundRiesenberg, R. A., Yeung, P. P., Rekeda, L., Sachs, G. S., Kerolous, M., & Fava, M. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14643 · Cited by 30
Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
Molnár, M. J., Molnár, V., Fedor, M., Csehi, R., Acsai, K., Borsos, B., & Grosz, Z. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.825532 · Cited by 27
“Next to studies proving cariprazine’s efficacy in schizophrenia, mania and depression associated with bipolar I disorder recent large-scale studies showed efficacy in adjunctive MDD treatment as well1 (26, 27).”
BackgroundThe preclinical discovery and development of cariprazine for the treatment of schizophrenia
Wesołowska, A., Partyka, A., Jastrzębska‐Więsek, M., & Kołaczkowski, M. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1471057 · Cited by 25
Seventy Years of Antipsychotic Development: A Critical Review
Shad, M. U. (2023) · Biomedicines · doi:10.3390/biomedicines11010130 · Cited by 25
“Cariprazine treatment was comparable to the placebo in weight gain and metabolic parameters (Figure 3), vital signs, sedation, prolactin, or QTc interval [118].”
BackgroundInfluentialHerman, A., Mansari, M. E., Adham, N., Kiss, B., Farkas, B., & Blier, P. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.113290 · Cited by 25
Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents
Kannarkat, G. T., Caroff, S. N., & Morley, J. F. (2022) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.695 · Cited by 20
Mallet, J., Gorwood, P. A. P. M., Strat, Y. L., & Dubertret, C. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz043 · Cited by 21
Antipsychotic Drugs and Dysregulated Glucose Homeostasis: A Systematic Review and Meta-Analysis
Smith, E. C. C., Agarwal, S. M., Panganiban, K. J., Maksyutynska, K., Monteiro, J., Lee, J., Prasad, F., Ji, A., Shah, D., Cavalier, S., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2240 · Cited by 21
An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder
Targum, S. D., Cameron, B. R., Ferreira, L., & MacDonald, I. D. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.10.010 · Cited by 18
Maldonado, G. M. M., & Schwartz, T. L. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000510 · Cited by 17
Batinić, B., Ristić, I., Žugić, M., & Baldwin, D. S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.784370 · Cited by 19
“When combining cariprazine with SSRIs or SNRIs clinicians should be aware of side effects such as akathisia, insomnia, and nausea, especially in doses of cariprazine higher than 2 mg/d (81).”
BackgroundWeiller, E., Weiss, C., Watling, C. P., Edge, C., Hobart, M., Eriksson, H., & D, M. F. M. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s146840 · Cited by 18
New Medications for Neuropsychiatric Disorders
Reddy, H. M., Poole, J. S., Maguire, G. A., & Stahl, S. M. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.008 · Cited by 17
Bai, B., Li, Y., Chen, X., Huang, J., Chen, Q., Du, X., Huang, C., & Yang, Y. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06783-7 · Cited by 15
“On the contrary, another study showed that caripra-zine 2–4.5 mg/d, compared with cariprazine 1–2 mg/d, showed superior efficacy on MADRS score, which was philosophical [37].”
InfluentialCookson, J., & Pimm, J. (2021) · BJPsych Advances · doi:10.1192/bja.2021.49 · Cited by 18
Tarzian, M., Ndrio, M., Kaja, S., Beason, E., & Fakoya, A. O. J. (2023) · Cureus · doi:10.7759/cureus.39309 · Cited by 20
“5 mg/day was effective and generally well-tolerated in adults with MDD who had inadequate responses to standard antidepressants [42].”
BackgroundInfluentialMansari, M. E., Ebrahimzadeh, M. A., Hamati, R., Iro, C. M., Farkas, B., Kiss, B., Adham, N., & Blier, P. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936891 · Cited by 15
“Aripiprazole and brexpiprazole have demonstrated consistent efficacy as an adjunct in patients with MDD (Citrome, 2015), whereas more clinical studies with cariprazine are ongoing to determine its efficacy (Durgam et al., 2016; Earley et al., 2018).”
BackgroundInfluentialReal-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies
Csehi, R., Dombi, Z. B., Sebe, B., & Molnár, M. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.827744 · Cited by 17
Thase, M. E., Yeung, P. P., Rekeda, L., Liu, M., & Varughese, S. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000528 · Cited by 14
Meyer, J. M., Cummings, M. A., & Proctor, G. J. (2016) · CNS Spectrums · doi:10.1017/s1092852916000821 · Cited by 13
“Lurasidone has an FDA indication for bipolar depression as monotherapy and as an adjunct to lithium or valproate, and double-blind monotherapy data in mixed unipolar depressive episodes, and cariprazine has recent positive data in a double-blind unipolar adjunctive trial.(52) While the combination of an atypical antip…”
BackgroundHoran, W. P., Kalali, A. H., Brannan, S. K., Drevets, W., Leoni, M. J., Mahableshwarkar, A. R., Martin, W. J., Rao, S., Reuteman-Fowler, C., Sauder, C. L., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae151 · Cited by 14
Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism
Mucci, F., Arone, A., Gurrieri, R., Weiss, F., Russomanno, G., & Marazziti, D. (2025) · Life · doi:10.3390/life15030391 · Cited by 16
“The authors also reported a parallel increase in mature BDNF protein levels in the prefrontal cortex, suggesting a possible neuroprotective action relevant to cognitive deficits in schizophrenia [126].”
McIntyre, R. S., Stahl, S. M., Shim, S. R., Pompili, M., Goldberg, J. F., Correll, C. U., Kwan, A. T. H., Dri, C. E., Xu, H., Vinberg, M., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0658 · Cited by 12
McIntyre, R. S., Maletic, V., Masand, P. S., Wilson, A. C., Yu, J., Adams, J. L., & Kerolous, M. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.05.026 · Cited by 13
Pessina, E., Martini, A., Raffone, F., & Martiadis, V. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1299368 · Cited by 12
Martins-Correia, J., Fernandes, L. A., Kenny, R. P. W., Salas, B., Karmani, S. J., Inskip, A., Pearson, F., & Watson, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.099 · Cited by 11
Exploring cariprazine as a treatment option for varied depression symptom clusters
Pejušković, B., Munjiza, A., & Pešić, D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1442699 · Cited by 11
Durgam, S., Earley, W. R., Kozauer, S. G., Mo, Y., Lakkis, H. D., Edwards, J. B., Kornstein, S. G., & Fava, M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250292 · Cited by 10
Self-citationMolecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation
Kowalczyk, M., Aebisher, D., Szpara, J., Czech, S., Bartusik‐Aebisher, D., & Henrykowska, G. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010344 · Cited by 11
“Cariprazine exerts antidepressant effects through precise modulation of dopaminergic and serotonergic neurotransmission, acting as a partial agonist at dopamine D3 and D2 receptors—with a marked preferential affinity for D3 receptors—and as a partial agonist at 5-HT1A receptors [77].”
Patient Functioning, Life Engagement, and Treatment Goals in Major Depressive Disorder
Correll, C. U., Ismail, Z., McIntyre, R. S., Rafeyan, R., & Thase, M. E. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.lu21112ah3 · Cited by 11
Use of Cariprazine in Psychiatric Disorders: A Systematic Review
Chhatlani, A., Farheen, S. A., Setty, M. J., & Tampi, R. R. (2018) · Annals of Clinical Psychiatry · doi:10.1177/104012371803000410 · Cited by 13
Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review
Poweleit, E. A., Colestock, M., Kantemneni, E. C., Strawn, J. R., Patino, L. R., DelBello, M. P., & Ramsey, L. B. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0106 · Cited by 10
A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression
Siwek, M., Chrobak, A. A., Sołtys, Z., Dudek, D., Krupa, A. J., & RYBAKOWSKI, J. K. (2021) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/132962 · Cited by 11
“Data from randomized controlled trials suggest second-generation antipsychotics as first-line treatment for acute bipolar depression, such as quetiapine [10], lurasidone [11-13], olanzapine (alone or combined with fluoxetine) [14] and cariprazine [15].”
Antidepressants in Bipolar Depression: An Enduring Controversy
Gitlin, M. J. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17306 · Cited by 12
Xie, M., Qiu, Y., Wang, M., Wei, X., Tao, Y., Duan, A., Shang, J., Gao, W., & Wang, Z. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.02.018 · Cited by 9
Cariprazine as a therapeutic option for schizophrenia: a drug evaluation
Mucci, F., Vecchia, A. D., Baroni, S., & Marazziti, D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1845315 · Cited by 10
Citrome, L., Reda, I., & Kerolous, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.040 · Cited by 9
Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis
Gill, H., Chen-Li, D. C. J., Haikazian, S., Seyedin, S., McIntyre, R. S., Mansur, R. B., Vincenzo, J. D. D., Phan, L., & Rosenblat, J. D. (2024) · CNS Spectrums · doi:10.1017/s1092852924000178 · Cited by 8
Yan, T., Greene, M., Chang, E. Y., Houle, C. R., Tarbox, M. H., & Broder, M. S. (2020) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s231824 · Cited by 8
Terao, I., & Kodama, W. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001862 · Cited by 7
Fasipe, O. J., & Ogunboye, I. (2024) · RPS Pharmacy and Pharmacology Reports · doi:10.1093/rpsppr/rqae017 · Cited by 9
A New Option for Depressed Patients Who Do Not Respond to Antidepressant Medications
Thase, M. E. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230039 · Cited by 7
McIntyre, R. S., Parikh, M., Ta, J. T., Waraich, S., Cohen-Stavi, C. J., Marci, C. D., & Nabulsi, N. A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2513766 · Cited by 6
“Cariprazine is a dopamine D 3 -preferring D 3 /D 2 and serotonin 5-HT 1A receptor partial agonist that was approved by the US Food and Drug Administration (FDA) as monotherapy to treat adults with schizophrenia or depressive, manic, and mixed episodes of BP-I between 2015 to 2019 and for adjunctive use with ADT to tre…”
InfluentialCariprazine on Psychosis: Beyond Schizophrenia – A Case Series
Bajouco, M., & Mota, D. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s355941 · Cited by 7
“It has also been shown to be effective in the treatment of unipolar depression due to its antidepressant effect.(13) In schizophrenia, cariprazine has proved to be effective not only in the treatment of positive symptoms but also of negative symptoms, being the only antipsychotic to effectively tackle the latter, to d…”
BackgroundAli, E., Latif, F., Mashkoor, Y., Sheikh, A., Iqbal, A., Owais, R., Ahmed, J., Naveed, S., Moeed, A., Ullah, I., et al. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104005 · Cited by 5
Barabássy, Á., Csehi, R., Dombi, Z. B., Szatmári, B., Brevig, T., & Németh, G. (2025) · Pharmaceuticals · doi:10.3390/ph18070995 · Cited by 4
“…on the C-SSRS in the single studies, no patient had suicidal behavior and most patients had no suicidal ideation either [36,37,39,40,42,43,45–47, 51, 52 In the pooled bipolar depression studies, at Week 6, statistically significant differences versus placebo were seen on Item 10 (Suicidal…”
InfluentialSelf-citationRenemane, L., & Rancāns, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1209077 · Cited by 4
“It further showed efficacy in the adjunctive treatment of major depressive disorder (21).”
BackgroundMasand, P. S., Clayton, A. H., Parikh, M., Laliberté, F., Germain, G., Mahendran, M., Martínez, C., & Nabulsi, N. A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2457872 · Cited by 3
“Cariprazine is effective as a treatment for schizophrenia 24 and bipolar disorder 19,25,26 , and as an adjunctive treatment for MDD 20,27 , with a favorable tolerability profile 20,25,26,28–30 .”
Насырова, Р. Ф. (2023) · Современная терапия психических расстройств · doi:10.21265/psyph.2023.86.41.003 · Cited by 3
Pich, E. M., Cavalleri, L., Toma, C., & Collo, G. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_348 · Cited by 3
Gill, J. S. (2023) · Healthcare · doi:10.3390/healthcare11182531 · Cited by 3
“It is categorized as a thirdgeneration antipsychotic medication and is currently approved by the USFDA for the treatment of adult schizophrenia [19–22] and bipolar I disorder patients (manic, mixed, and depressed episodes) [23], as well as for the adjunctive treatment of major depressive disorder [24,25].”
BackgroundCariprazine: Pharmacology and Use in the Clinical Management of Psychiatric Disorders
Reyad, A. A., & Mishriky, R. S. L. (2019) · Psychiatric Annals · doi:10.3928/00485713-20190213-01 · Cited by 4
Dopamine D 2 Partial Agonists – Discovery, Evolution, and Therapeutic Potential
Jacobson, M. A., Childers, W. E., & Abou-Gharbia, M. A. (2019) · Wiley eBooks · doi:10.1002/9783527814695.ch4 · Cited by 6
A Historical Perspective on the Dopamine D3 Receptor
Sokoloff, P., & Foll, B. L. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_315 · Cited by 5
Davis, J. M. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.001 · Cited by 3
Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania
Palacios‐Garrán, R., Llorca-Bofí, V., Arteaga-Henríquez, G., & del Agua, E. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.828088 · Cited by 2
Recommendation for a Therapeutic Reference Range of Cariprazine—A Short Communication
Sattaf, F., Scherf‐Clavel, M., Unterecker, S., Reif, A., & Hahn, M. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001152 · Cited by 2
The Polypharmacology of Cariprazine and its Implications to Clinical Indications
Egyed, A., Kiss, D. J., & Keserű, G. M. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch25 · Cited by 2
Aga, V. M., Shad, M. U., Zhu, H., & Salzman, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-800136-3.00023-5 · Cited by 3
Оленева, Е. В., & Мосолов, С. Н. (2021) · Современная терапия психических расстройств · doi:10.21265/psyph.2021.26.96.001 · Cited by 2
Metadata
- Authors
- Durgam, S., Earley, W., Guo, H., Li, D., Németh, G., Laszlovszky, I., Fava, M., & Montgomery, S. A.
- Corresponding author
- Durgam, Suresh
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-03-23
- Volume
- 77
- Issue
- 03
- Pages
- 371-378
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2316471784
- Cited by
- 125
- References
- 5
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 17 · 2023: 15 · 2022: 18 · 2021: 7 · 2020: 8 · 2019: 11 · 2018: 13 · 2017: 9 · 2016: 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- cariprazine, major depressive disorder, adjunctive therapy, atypical antipsychotics, antidepressant resistance, akathisia, treatment-emergent adverse events, dose comparison, suicidality, Montgomery-Asberg Depression Rating Scale, tolerability, metabolic parameters, insomnia, nausea, antidepressant efficacy
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Major, Dose-Response Relationship, Drug, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Piperazines, Antipsychotic Agents, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.